Please login to the form below

Not currently logged in

Daily Brief: GDPR and NHS Opt Out Day, BioMarin's new rare disease approval and more

It's not just the GDPR's big day, plus news from Medigene and Pfizer

Digital skills gap hinders UK healthcare innovation

Brexit UK EU life sciences pharma biotechReport calls for greater emphasis on HCPs’ digital and data literacy education

FDA starts review of Sanofi’s oral type 1 diabetes drug

Sanofi logo

FDA clears Dova drug for liver-related low blood platelets

FDA headquarters White OakDrug is in the same class as Novartis’ Promacta/Revolade

AZ gets US approval for Veltassa rival Lokelma

AstraZeneca AZBut GlobalData predicts Veltassa has the edge due to positive data in chronic hyperkalaemia

Novartis, Amgen set low price for first CGRP migraine drug

Novartis buildingAimovig has a list price of $6,900 per year

Pharma and biotech leaders back ’no deal’ Brexit warning

Ongoing division in Conservative party means 'no deal' remains a possibility

Breakthrough Device status for novel blood filtering immunotherapy

FDA headquarters White OakNovel technology aims to reactivate immune system in cancer patients

Despite FDA concerns, Akcea rare disease drug clears FDA panel

FDA headquarters White OakFDA now set to deliver final verdict by 30 August

KeysMoving times

Continuity and stability are vital when it comes to the EMA's relocation when it leaves London

Latest regulatory appointments

Featured jobs

Subscribe to our email news alerts


Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Beyond the event
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...